El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

867654.pdf (2.26 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2024-05-20

Llicència de publicació

cc-by (c) Valdez Capuccino, L. et al., 2024
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/219480

CDK9 inhibition as an effective therapy for small cell lung cancer

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1038/s41419-024-06724-4

Resum

Treatment-naïve small cell lung cancer (SCLC) is typically susceptible to standard-of-care chemotherapy consisting of cisplatin and etoposide recently combined with PD-L1 inhibitors. Yet, in most cases, SCLC patients develop resistance to first-line therapy and alternative therapies are urgently required to overcome this resistance. In this study, we tested the efficacy of dinaciclib, an FDA-orphan drug and inhibitor of the cyclin-dependent kinase (CDK) 9, among other CDKs, in SCLC. Furthermore, we report on a newly developed, highly specific CDK9 inhibitor, VC-1, with tumour-killing activity in SCLC. CDK9 inhibition displayed high killing potential in a panel of mouse and human SCLC cell lines. Mechanistically, CDK9 inhibition led to a reduction in MCL-1 and cFLIP anti-apoptotic proteins and killed cells, almost exclusively, by intrinsic apoptosis. While CDK9 inhibition did not synergise with chemotherapy, it displayed high efficacy in chemotherapy-resistant cells. In vivo, CDK9 inhibition effectively reduced tumour growth and improved survival in both autochthonous and syngeneic SCLC models. Together, this study shows that CDK9 inhibition is a promising therapeutic agent against SCLC and could be applied to chemo-refractory or resistant SCLC.

Matèries

Càncer de pulmó, Inhibidors enzimàtics, Metabolisme, Quimioteràpia

Matèries (anglès)

Lung cancer, Enzyme inhibitors, Metabolism, Chemotherapy

Citació

Col·leccions

Articles publicats en revistes (Biomedicina)

Citació

VALDEZ CAPUCCINO, L., KLEITKE, T., SZOKOL, B., SVAJDA, L., MARTIN, F., BONECHI, F., KREKO, M., AZAMI, S., MONTINARO, A., WANG, Yan, NIKOLOV, V., KAISER, L., BONASERA, D., SAGGAU, J., SCHOLZ, T., SCHMITT, A., BELEGGIA, F., REINHARDT, H. c., GEORGE, J., LICCARDI, G., WALCZAK, H., TOVARI, J., BRAEGELMANN, J., MONTERO, J., SOS, M. l., ORFI, L., PELTZER, N.. CDK9 inhibition as an effective therapy for small cell lung cancer. _Cell Death and Disease_. 2024. Vol. 15, núm. 5, pàgs. 345. [consulta: 31 de desembre de 2025]. ISSN: 2041-4889. [Disponible a: https://hdl.handle.net/2445/219480]

Exportar metadades

JSON - METS

Compartir registre